## Regulatory Pathways for Non-Invasive Neuromodulation Devices – EU Perspective

Non-Invasive Neuromodulation of the Central Nervous System: IOM, Washington DC, March 2<sup>nd</sup> and 3<sup>rd</sup>, 2015

### Ibim Tariah Ph.D



Copyright © 2012 BSI. All rights reserve

## **Presentation Overview**

- 1. Who is involved in CE Marking?
  - EU Commission
  - Competent Authorities
  - Notified Bodies
  - Manufacturers
- 2. Why bother with CE Marking?
- 3. How do Manufacturers CE Mark Devices?
  - Is it a device?
  - What is the classification?
- 4. Conformity Assessment Routes
- 5. Technical Documentation & Essential requirements
  - Device-Drug Combination products
  - Declaration of Conformity

**CE Mark Affixation** 



## Who is involved?

## Who are the Players?

## • EU Commission: Situated in Brussels

- 'Civil Service'; Draft Directives & Regulations; Keep list of Harmonised Standards up to date
- Member States: 28 of them, represented by "Competent Authorities"
  - Transpose Directives into National Law; Enforce requirements

## • Notified Bodies: Over 60, situated in nearly all the Member States

- Designated by CA's
- Conduct Conformity Assessment

## Manufacturers

• Uncountable, situated worldwide



# Why bother?

Copyright © 2012 BSI. All rights reserved.




## **European Union**

28 Member States + Norway, Iceland, Switzerland & Lichtenstein + Turkey

505,000,000 People 23 Official Languages

Mutual Recognition

- Australia
- Taiwan
- Saudi Arabia




Regulatory Pathways for Non-Invasive Neuromodulation Devices

## 93/42/EEC (MDD) and 90/385/EEC (AIMD)?

Copyright © 2012 BSI. All rights reserved

Manufacturer: Product to CE Mark



## Is it a Device?



Copyright © 2012 BSI. All rights reserve

9

## Medical Device – 93/42/EEC









































bsi.

## <u>93/42/EEC</u>

'Medical device' means any instrument, apparatus, appliance, software, material or other article ... intended by the manufacturer to be used for human beings for the purpose of:

- diagnosis, prevention, monitoring, treatment or alleviation of disease,
- diagnosis, monitoring, treatment, alleviation of or compensation for injury or handicap,
- investigation, replacement or modification of anatomy or physiological process,
- control of conception,

and which does not achieve its principal intended action ... by pharmacological, immunological or metabolic means, but which may be assisted in its function by such means.

# What is the Classification?


Classification – Based on Manufacturer's Intended Purpose

## **Device Classification:**

Notified Body + Competent Authority Assessment

Notified Body Conformity Assessment

Self-Certification



#### Annex IX Classification Criteria

.... Para 2.1: "Application of the classification rules shall be governed by the intended purpose of the devices"

### • Duration of contact:

• Transient, Short term, Long term

### • Degree of invasiveness:

- Implantable, Surgical, Body orifice
- Anatomy affected
- Active / Non-active

**Duration of Contact** 

- Transient: <60 minutes
- Short term: ≤30 days
- Long term: >30 days

• Immediate replacement by similar device is a continuation of original use

### Degree of Invasiveness

### Invasive

• Penetrates inside the body via a body orifice or through the surface

### Body orifice

• Natural opening or permanent artificial opening, eg stoma

## Surgical

• Penetrating the surface in the context of surgical intervention

### Annex IX Definitions

- Reusable
- Active
- Implantable
- Central Circulatory and Nervous Systems
  - 2007/47/EC increases scope of CCS

### 18 Classification Rules

- 1 4 Non invasive devices
- 5 8 Invasive devices
- 9 12 Active devices
- 13 18 Special rules

### How to Classify

- 1. Intended purpose
- 2. Confirm it is a medical device
- 3. Consider the definitions
- 4. Consider the implementing rules
- 5. Decide on the applicable rule
- 6. Classify

# Conformity Assessment



Copyright © 2012 BSI. All rights reserved


20

### Conformity Assessment Annexes

| Product Annexes    |                    | Quality System<br>Annexes |   |
|--------------------|--------------------|---------------------------|---|
| Annex II<br>Para 4 | Design Examination | Annex II<br>Para 1-3, 5-8 | Design, Manufacture<br>and Final Inspection |
| Annex III          | Type Test          | Annex V                   | Manufacture and Final<br>Inspection         |
| Annex IV           | Batch Release      | Annex VI                  | Final Inspection and<br>Testing             |



### Class II b Device




Declaration of Conformity & CE Marking

# 

hsi

### Class III Device



bsi.

# Technical Documentation & Essential Requirements



## 93/42/EEC – Annex VII

The technical documentation must allow assessment of the conformity of the product with the requirements of the Directive. **It must include in particular:** 

- general description of the product and intended use(s),
- design drawings, methods of manufacture, diagrams of components,
- explanations necessary to understand the operations of the product,
- results of the risk analysis,
- list of harmonised standards, applied in full or in part,
- descriptions of the solutions adopted to meet the ERs,
- in the case sterile products validation report,

## 93/42/EEC – Annex VII

and ... :

- results of the design calculations and inspections carried out,
- if the device is to be connected to other device(s), proof must be provided that it conforms to the ERs,
- solutions adopted as referred to in Annex I,
- pre-clinical evaluation,
- clinical evaluation in accordance with Annex X,
- label and instructions for use.

## General Essential Requirements 1-6: Summary

- 1. Safe benefits outweigh risk
- 2. State of the art inform of residual risks
- 3. Perform as intended
- 4. Lifetime defined
- 5. Packaging suitable for transport and storage
- 6. Side effects acceptable

## 6a. Clinical data

## **Notified Bodies Assessment: Device-Drug Combination**

Key Essential Requirements:

• ER 1

- Devices must not compromise the clinical condition of patients
- Risks are acceptable when weighed against the benefits to the patient

• ER 7.4

- Verification of safety, quality and usefulness of the substance ... by analogy with .... Directive 2001/83/EC
- NB must consult a Drug CA before taking its decision
- NB shall only consult drug CA having verified the usefulness of the substance taking into account the intended purpose of the device
- NB will give due consideration to the views of the Drug CA when making its decision
- NB will almost certainly not go against a negative Drug CA opinion

## **Notified Bodies Assessment: Device-Drug Combination**

• Review Process Overview:

## Device Aspects:

• Reviewed by NB per requirements in appropriate Directive

## Medicinal Aspects:

- NB conducts initial review of **USEFULNESSS** of medicinal substance.
- Above usefulness report together with Medicinal Data package is reviewed by Medicinal CA/EMA
- Medicinal CA/EMA review focus is on: QUALITY and CLINICAL SAFEFTY of the Medicinal substance.
- Medicinal CA/EMA provides final review report to NB who makes a Certification decision.

## **Available Guidance on Classification**

- Speak to NBs with experience of Device Drug Combinations
- MEDDEV 2.1/3 Rev 3
- MHRA Bulletin No. 17 Medical devices and Medicinal Products
- MHRA Guidance Note No 8 A Guide to what is a Medicinal Product
- Manual on borderline and Classification in the Community Regulatory Framework for medical devices

http://ec.europa.eu/health/medicaldevices/documents/borderline/index\_en.htm

## **Notified Bodies Assessment: Device-Drug Combination**

### Considerations for device-drug combinations:

- Properties of medicinal substance considered in manufacturing controls, processing parameters and storage conditions
- Appropriate controls on the medicinal substance to assure quality in the device is maintained
- Stability should be conducted in accordance with ICH
- Quality Management System considers the importance of the medicinal substance as well as the device aspects
- Controls taken to minimise risk of harm to end user
- Use relevant guidance documents from EMA where relevant

http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general\_content\_000043.jsp&mid=WC0b01ac05800240cb

• Dossier in line with MEDDEV 2.1.3 or CTD format

## **Notified Bodies Assessment: Device-Drug Combination**

### Certification and CE-mark:

CA/EMA provide a scientific opinion report to NB

- Positive Outcome: NB issues EC Design Exam Cert and informs CA/EMA of its decision. Manufacturer prepares Declaration of Conformity and applies CE Mark
- Negative Outcome: The NB may not issue the Certificate

### ERs – Summary

• Devices must be safe and fit for their intended purpose

- Manufacturers must demonstrate the Essential Requirements have been addressed and where appropriate met before applying CE mark
- Evidence of compliance shall be included or referenced in the manufacturers technical documentation
- Clinical data must be properly established and must be kept up to date
- May use standards to demonstrate conformity (preferably harmonized)

Risk Management


Per EN 14971:2012



Copyright © 2013 BSI. All rights reserved.

Essential Requirement #6

## "Benefits > Risks"





# Declaration of Conformity

Copyright © 2012 BSI. All rights reserved

36

## DOC NB-Med Consensus Statement:

| Declaration of Conformity   |  |
|---|--|
| Name and address of the manufacturer (and authorised representative)  |  |
| Name, type or model   |  |
| The DoC may cover particular lots, batches, serial numbers, particular products types and/or particular periods of manufacture.                           |  |
| 'We hereby declare that the above mentioned devices<br>comply with the legislation of the UK transposing<br>European Medical Devices Directive 93/42/EEC' |  |
| Date from which the DoC is valid  |  |
| Name, position and signature of the person, who is approving the DoC  |  |
|   |  |

## Conclusions

- Medical Device: Definition & Scope of the MDD (or AIMD?) .
- Classification consider ALL applicable Rules.
- Conformity Assessment
- Compliance with ALL applicable Essential Requirements
  - Clinical Data (Clinical Equivalence)
  - Risk Management
  - Labeling
- Device-Drug Combinations, MUST consult with a CA
- Affix CE Mark .....and Place on the Market



### Any Questions....and Contact Us



Ibim Tariah Ph.D Name: Technical Director, HealthCare Solutions Title: BSI Group Americas Inc, Address: 12950 Worldgate Drive, Suite 800 Monument II, Herndon VA 20170. USA. +1 703 674 1994 Work<sup>.</sup> Ibim.Tariah@bsigroup.com Email: http://medicaldevices.bsigroup.com/en-US/ Links:



# bsi.

## ...making excellence a habit."